Skip to main content Skip to section navigation Skip to footer

chevron_leftBack to Evommune.com

Check Out the EADV Webinar of Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria.

Click Here

About Us
Our Science
Our Pipeline
Join Us
- Our Culture
- Job Openings
Investors & Media

Select Page

Overview
Company Info
News & Events
Stock Data
Financial & Filings
- Financial Results
- SEC Filings
Corporate Governance
Back to Evommune.com

IR Calendar

Overview

Overview
Company Info
News & Events
Stock Data
Financial & Filings
- Financial Results
- SEC Filings
Corporate Governance

News & Events
Press Releases
IR Calendar
Email Alerts

EVO570: Potential Best-in-Class VAV1 Molecular Glue Degrader

Nov 5, 2026 8:30 am EST

Company Profile
Contacts
RSS News Feed
Sitemap
Accessibility Statement

About Us

Overview
Leadership
Collaborating
Contact

Our Science

Approach
Disease Focus
Publications & Posters

Our Pipeline

Development Pipeline
IL-18BP Fusion Protein
MRGPRX2 Antagonist
TLR 7/8 Antagonist
Clinical Trials

Join Us

Our Culture
Job Openings

Investors & Media

Overview
Company Info
News & Events
Stock Data
Financial & Filings
Corporate Governance

© 2026 Evommune, Inc.

Privacy Policy
Terms of Use

Website by 22 Fillmore